Vaxcyte (FRA:5VA) Accounts Payable & Accrued Expense : €78.51 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Vaxcyte Accounts Payable & Accrued Expense?

Vaxcyte's quarterly accounts payable & accrued expense increased from Sep. 2024 (€91.82 Mil) to Dec. 2024 (€108.62 Mil) but then declined from Dec. 2024 (€108.62 Mil) to Mar. 2025 (€78.51 Mil).

Vaxcyte's annual accounts payable & accrued expense increased from Dec. 2022 (€31.56 Mil) to Dec. 2023 (€116.61 Mil) but then declined from Dec. 2023 (€116.61 Mil) to Dec. 2024 (€108.62 Mil).

Vaxcyte Accounts Payable & Accrued Expense Historical Data

The historical data trend for Vaxcyte's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxcyte Accounts Payable & Accrued Expense Chart

Vaxcyte Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

38.28

17.69

31.56

116.61

108.62

Vaxcyte Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															70.67	64.19	91.82	108.62	78.51

Vaxcyte Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Vaxcyte Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxcyte Inc (FRA:5VA) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

PCVX:USA 5VA:Germany

Address

825 Industrial Road, Suite 300, San Carlos, CA, USA, 94070

Website

https://www.vaxcyte.com

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

Vaxcyte Headlines

No Headlines